– FRANCE, Paris – Artedrone, a medtech portfolio company developing an autonomous micro-robotic platform to perform and democratize mechanical thrombectomy procedures to treat patients suffering from a stroke, announced the appointments of Nnamdi Njoku and Dan Raffi to its Board of Directors, and of Liane Teplitsky as CEO.
About Nnamdi Njoku
Nnamdi Njoku is a highly experienced and successful business leader with global operating experience at multinational healthcare and medical technology companies, including Medtronic and Zimmer Biomet. He was recently appointed as EVP & COO at Omnicell where he will help scale pharmacy automation drive multi-year innovation and excellence and lead the company’s global operations. His leadership in both neuroscience and cardiovascular businesses, along with his operating acumen will help drive excellence and product performance at Artedrone.
Nnamdi Njoku has an MBA from Cornell University and holds a bachelor’s degree in accounting from the University of St. Thomas.
About Dan Raffi
Dan Raffi is a visionary & results-driven executive with over 25 years of leadership experience across global markets, driving growth and operational excellence in the medical device and pharmaceutical industries. He is SVP & Global CCO at Guerbet, and before that was COO at Sim & Cure. He has spent the majority of his career in Neuroscience, as a leader with Medtronic Neurovascular and Neuromodulation and with Allergan (Abbvie) Neuroscience division. He is currently a board member of the French Healthcare Association. Dan’s extensive experience in the Neurovascular market will be a key asset to Artedrone.
Dan Raffi has an MBA from the ESCP business school and a pharmacist diploma from Nantes University.
About Liane Teplitsky
Liane Teplitsky is a successful seasoned senior executive in the medical device and technology industry with achievements in building, leading, and growing innovative businesses that elevate the standard of patient care. With an extensive background in R&D and a passion for advancing intelligent and life-changing medical technologies, she has cultivated expertise in leading business strategy, clinical data development, and commercialization for multimillion-dollar global medical technology franchises. Additionally, Liane has demonstrated excellence in building and leading high-functioning, highly engaged teams. Most recently she was President, Global Robotics, Technology & Data Solutions at Zimmer Biomet where she led the global growth and development of the company’s portfolio of robotics and digital health technologies. Before Zimmer Biomet, Liane spent nearly a decade in executive leadership roles at Abbott and St. Jude Medical, with a focus on cardiac diseases and diagnostics.
Liane Teplitsky said: “I am excited to be joining a fantastic team that is dedicated to bringing game-changing technology to market. Ischemic stroke patients deserve to have the best treatment possible, regardless of their location. I believe SASHA has the ability to democratize the mechanical thrombectomy procedure and will save and improve millions of lives around the world.”
Liane Teplitsky holds a Master of Science in Biomedical Engineering from Duke University, a Bachelor of Science in Electrical Engineering, and a Bachelor of Science in Physiology from the University of Saskatchewan.
About Artedrone
Artedrone, founded by Truffle Capital, is currently developing SASHA, an autonomous micro-robotic solution for mechanical thrombectomy.
Strokes are the second cause of mortality and the third cause of disability worldwide. In particular, acute ischemic strokes are extreme emergencies affecting 7.6 million people worldwide every year according to the World Stroke Organization.
Stroke outcomes are heavily dependent on the patient’s access to immediate care, with mechanical thrombectomy for ischemic stroke treatment being the current standard of care. A patient who receives thrombectomy treatment within the first six hours after the event has up to three times better outcome.
By introducing SASHA, Artedrone seeks to address the lack of stroke centers & expert interventionalists by democratizing the thrombectomy procedure and allowing for greater adoption of thrombectomy procedures.
For more information: https://www.artedrone.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.